WASHINGTON, D.C., June 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) and Eli Lilly and Company (NYSE: LLY - News) today announced detailed findings from a study that showed BYETTA® (exenatide) injection lowered blood glucose levels for people with type 2 diabetes who had not achieved target blood glucose levels despite the use of a thiazolidinedione (TZD) with or without metformin. Patients using BYETTA showed improvements in three important measures of blood glucose control: fasting blood glucose, postprandial blood glucose and hemoglobin A1C (A1C), which improved by approximately 0.9 percent compared to the control group. Sixty-two percent of study participants using BYETTA who completed the full study reached target A1C of 7 percent or less. Less than 7 percent is the target for good glucose control as recommended by American Diabetes Association (ADA).
